Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.

Biotech SG&A Expenses: Amicus vs. Arrowhead

__timestampAmicus Therapeutics, Inc.Arrowhead Pharmaceuticals, Inc.
Wednesday, January 1, 20142071700024419536
Thursday, January 1, 20154726900034718089
Friday, January 1, 20167115100040998209
Sunday, January 1, 20178867100032022880
Monday, January 1, 201812720000019110051
Tuesday, January 1, 201916986100026556257
Wednesday, January 1, 202015640700052275890
Friday, January 1, 202119271000080981000
Saturday, January 1, 2022213041000124431000
Sunday, January 1, 202327527000090932000
Monday, January 1, 202498761000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Amicus Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Amicus Therapeutics has seen a significant increase in SG&A expenses, growing by over 1,200% from 2014 to 2023. In contrast, Arrowhead Pharmaceuticals experienced a more modest rise of approximately 300% during the same timeframe.

The data reveals that Amicus Therapeutics consistently outspent Arrowhead Pharmaceuticals, with a peak in 2023 where their expenses were nearly three times higher. This trend highlights Amicus's aggressive investment in administrative and sales functions, possibly reflecting a strategy to expand market presence. Meanwhile, Arrowhead's steadier growth in expenses suggests a more conservative approach. Notably, data for 2024 is incomplete, indicating potential changes in future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025